two muskoxen headbutting
Muskoxen Headbutts May Cause Brain Damage: Study
Researchers report molecular evidence of traumatic brain injury in headbutting animals, but other experts aren’t convinced.
ABOVE: © ISTOCK.COM, Frank Fichtmüller
Muskoxen Headbutts May Cause Brain Damage: Study
Muskoxen Headbutts May Cause Brain Damage: Study

Researchers report molecular evidence of traumatic brain injury in headbutting animals, but other experts aren’t convinced.

Researchers report molecular evidence of traumatic brain injury in headbutting animals, but other experts aren’t convinced.

ABOVE: © ISTOCK.COM, Frank Fichtmüller

Alzheimer's Disease

Tiled blue-gray MRI readouts of a human brain.
Cancer Tied to Reduced Risk of Alzheimer’s Disease
Dan Robitzski | Apr 14, 2022
Observational evidence for the connection is solidifying, and some clues are emerging about the mechanisms that may explain it.
Ramified cells in a lilac background
Could Vitamin Supplementation Help Alzheimer’s Patients?
Alejandra Manjarrez | Apr 11, 2022
Niacin, a form of vitamin B3 used to treat cardiovascular disease, helps immune cells in the brain fight neurodegenerative diseases such as Alzheimer’s in mice models, according to recent studies. Researchers hope that human clinical trials will swiftly follow.
Explore how scientists determine the atomic structures of protein aggregates
Revolutionizing Neurodegeneration Research with Cryo-EM
The Scientist Creative Services Team, Thermo Fisher Scientific | Feb 22, 2022
Advancements in cryo-EM technology allow researchers to develop drugs and diagnostic tools for neurodegenerative diseases.
A model of a brain made of many stacked, thin layers of brightly-colored material.
Neurons Damaged in Dementia Recognize Interruptions to Patterns
Anna Napolitano | Mar 16, 2022
A new study reveals a network of neurons that, when disrupted, impairs adaptation to new circumstances in several types of dementia.
mice on wheel and ground
Exercise-Associated Protein Boosts Brain Function in Mice
Chloe Tenn | Dec 9, 2021
A study that transfused plasma from active to inactive mice suggests the protein clusterin enhances cognition.
40499-ts-metabolomiclinks-el800x560
Metabolomic Links Between Environmental Exposures and Human Health
The Scientist Creative Services Team | Oct 25, 2021
Experts discuss how untargeted metabolomic studies connect environmental factors with human disease.
Microscopic photograph of brain tissue demonstrating the characteristics of Alzheimer's disease
David Gate Probes Links Between Alzheimer’s and the Immune System
James M. Gaines | Nov 1, 2021
The Northwestern University researcher studies how adaptive immune cells influence neurodegenerative disease.
An artist's rendition of an RNA molecule in light blue on a dark blue background
Same RNA Acts in Neurodegeneration and Cancer
Abby Olena | Oct 29, 2021
The long noncoding RNA MINCR, implicated in ALS and Alzheimer’s disease as well as several types of cancer, appears to function differently when present at high versus low levels.
3-800x560
Fecal Transplant Restores Youth to Old Mice
Roni Dengler, PhD | Aug 30, 2021
Microbiota from young mice reversed some aspects of aging and enhanced brain health in aged mice.
Illustration of neurons in white with myelin in blue
Repurposed Drug Reverses Signs of Alzheimer’s in Mice, Human Cells
Jef Akst | Oct 12, 2021
Researchers say they hope to launch a clinical trial to test bumetanide, a diuretic approved in 2002, but how it might improve neural functioning is unclear.
Colored artistic rendition of neurons and plaque buildup
Alzheimer’s Risk Gene Paradoxically Protects Against Memory Loss
Chloe Tenn | Oct 8, 2021
A new study links a variant of the apolipoprotein E gene called APOE ε4 to better memory in older age, even in the presence of amyloid plaques—a possible explanation for the variant’s persistence despite its association with an increased risk of Alzheimer’s disease.
LabTalk Podcast - Understanding Microglial Response in Alzheimer’s Disease
The Scientist Creative Services Team, 10x Genomics | Jul 30, 2021
Single-cell technologies reveals subpopulations of microglia that play distinct roles in diseased and healthy brains.
Brain cells with electrical firing. 3D rendering.
Microglia as Therapeutic Targets in Neurodegenerative Diseases
Sruthi S. Balakrishnan | Oct 1, 2021
Pharmaceutical companies ramp up efforts to get the brain’s immune cells to help treat Alzheimer’s disease and other conditions, but not everyone agrees the approach will be effective.
white mouse on wheel
Putative Exercise Hormone Irisin Boosts Mouse Brainpower
Sophie Fessl | Sep 10, 2021
Mice lacking irisin didn’t exhibit the cognition improvements that typically follow exercise, and in mouse models of Alzheimer’s disease, treatment with the hormone reduced cognitive decline.
Inhaled Antibody Fragments Protect Infected Animals Against COVID-19
Roni Dengler, PhD | Jun 14, 2021
Tiny but powerful nanobodies may be the innovation that snuffs out the pandemic.
artistic drawing of neuron filled with tau proteins
Genes for Alcohol Use Disorder and Alzheimer’s Risk Overlap: Study
Emma Yasinski | Aug 24, 2021
Genetic, transcriptomic, and epigenetic data reveal molecular mechanisms tying these disorders to each other and to immune disfunction.
A stamp with a checkmark and the word FDA approved lying on its side on a white background.
Biogen Defends Newly Approved Alzheimer’s Drug
Jef Akst | Jul 27, 2021
The US Food and Drug Administration has called for a federal investigation of its own regulatory review process after widespread criticism of its decision on Aduhelm.
The Scientist Speaks Ep. 16 - At the Breaking Point: Mitochondrial Deletions and the Brain
The Scientist Creative Services Team | Mar 31, 2021
Researchers characterize large mitochondrial deletions to understand their implications in neurological disorders.
Updated
blue and white sign for the entrance to the FDA that says U.S. Department of Health and Human Services Food and Drug Administration
Biogen’s Alzheimer’s Drug Gets FDA Approval, Mixed Reviews
Kerry Grens | Jun 7, 2021
A lackluster performance in clinical trials of the monoclonal antibody aducanumab has left some experts unconvinced of its benefit.